濮阳东方医院男科咨询电话濮阳东方妇科医院看病好不好,濮阳东方妇科医院技术很专业,濮阳东方医院妇科位置,濮阳东方妇科医院上班时间,濮阳东方医院看早泄收费透明,濮阳东方医院看阳痿价格透明,濮阳东方医院治疗阳痿价格收费合理

ATHENS, Nov. 11 (Xinhua) -- The third Forum on the Development of Tibet concluded here on Friday after discussions on efforts to promote the world's understanding of Tibet and enhance the cooperation between China and the rest of the world with regards to Tibet's development.This year marks the 60th anniversary of Tibet's peaceful liberation. During the two-day event, delegates from Greece, Britain, France, Germany, India and Nepal expressed their opinions on Tibet's modernization and put forward valuable advice and suggestions based on their own experience and research findings.Some of the foreign delegates have visited Tibet many times before. Narasimhan Ram, Editor-in-chief of The Hindu from India and Brendan O'Neill, editor of the British magazine Spiked spoke positively about the preferential polices and financial support of the Chinese central government and other parts of China for the region.During the Forum, Wang Chen, head of the Chinese State Council Information Office met with the Greek political leaders and journalists from mainstream media.People got an opportunity to learn more about China as Nyima Tsering, Vice Chairman of the Standing Committee of the People's Congress of the Tibet Autonomous Region, introduced the development of Tibet and the Chinese government's policy towards the region.A number of Greek mainstream media covered the Forum.Over the past 60 years, Tibet has achieved a huge development in both its social structure and socio-economic development, said a communique released upon the end of the forum.It also foresees a great potential of cooperation with the international community in energy, environment, education and healthcare development for the region.The forum has facilitated better understanding of Tibet in the international community and will help to promote faster and better development of the autonomous region, the Communique said.

BEIJING, Jan. 5 (Xinhua) -- The U.S. Secretary of Treasury Timothy Geithner will visit China from Jan. 10 to 11 as a special representative of the U.S. President Barack Obama, Chinese Foreign Ministry spokesman Hong Lei announced on Thursday.Timothy Geithner's visit is at the invitation of Chinese Vice Premier Wang Qishan, said Hong.Chinese top leaders will meet with Timothy Geithner and exchange views with him on issues concerning Sino-US economical relations and the world's economic and financial situations, Hong said.

WASHINGTON, Nov. 14 (Xinhua) -- Vitamin D levels are significantly lower in patients with recurrent inflammatory spinal cord disease, according to a study published online Monday in Archives of Neurology.Vitamin D is a steroid vitamin that promotes the intestinal absorption and metabolism of calcium and phosphorus. In recent years, low levels of vitamin D have been linked to a variety of autoimmune conditions, including multiple sclerosis (MS). However, the importance of vitamin D in monophasic or recurrent non-MS spinal cord diseases including transverse myelitis and neuromyelitis optica is unknown, according to background information in the article.Transverse myelitis (TM) is a disease of the spinal cord in which there is involvement of the myelin sheath that protects nerve fibers; symptoms include back pain and weakness in the legs. Neuromyelitis optica (NMO) is a disease of the central nervous system that affects the optic nerves and spinal cord.Maureen Mealy, of Johns Hopkins University and colleagues investigated the association between low serum vitamin D levels and recurrent spinal cord disease. They analyzed data on vitamin D levels among 77 patients with monophasic (having only one phase or stage) and recurrent inflammatory diseases of the spinal cord, adjusting for season, age, sex, and race. The study found that vitamin D levels were significantly lower in patients who developed recurrent spinal cord disease."Our findings suggest that there may be an association between lower total 25-hydroxyvitamin D levels in patients with recurrent TM/NMO/ spectrum disorders as compared with their counterparts with monophasic disease," the authors report. They suggest that future studies are needed to further assess the relationship between vitamin D and recurrent spinal cord disease.

BEIJING, Nov. 28 (Xinhuanet) -- Scientists in Canada have raised a prospect of reversing Alzheimer's disease by deep brain stimulation, according to media reports Monday.The technique here is known as deep brain stimulation -- applying electricity directly to regions of the brain. It has been used in tens of thousands of patients with Parkinson's as well as having an emerging role in Tourette's Syndrome and depression.The study at the University of Toronto took six patients with the condition. Deep brain stimulation was applied to the fornix -- a part of the brain which passes messages onto the hippocampus.Lead researcher Prof Andres Lozano said you would expect the hippocampus to shrink by five per cent on average in a year in patients with Alzheimer's.After 12 months of stimulation, he said one patient had a five per cent increase and another had an eight per cent increase.Prof Lozano told BBC: "This is the first time that brain stimulation in a human being has been shown to grow an area of your brain.""It was an amazing finding for us," he said.The findings were presented at the Society for Neuroscience conference in November but they have yet to be published in an academic journal.To test whether this is really working, rather than being a fluke result, the researchers are going to perform a larger trial.

WASHINGTON, Nov. 11 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved HEMACORD, the first licensed hematopoietic progenitor cells-cord cell therapy.HEMACORD is indicated for use in hematopoietic stem cell transplantation procedures in patients with disorders affecting the blood forming system. For example, cord blood transplants have been used to treat patients with certain blood cancers and some inherited metabolic and immune system disorders."The use of cord blood hematopoietic progenitor cell therapy offers potentially life-saving treatment options for patients with these types of disorders," said Karen Midthun, director of FDA's Center for Biologics Evaluation and Research, in a statement.HEMACORD contains hematopoietic progenitor cells (HPCs) from human cord blood. Cord blood is one of three sources of HPCs used in transplants. The other two are bone marrow and peripheral blood. Once these HPCs are infused into patients, the cells migrate to the bone marrow where they divide and mature. When the mature cells move into the bloodstream they can partially or fully restore the number and function of many blood cells, including immune function.